Dr John Buscombe

British Nuclear Medicine Society

Dr John Buscombe is the President of the British Nuclear Medicine Society and works as a Consultant Physician in Nuclear Medicine in Cambridge.

dont miss

Theranostics in prostate cancer new or false dawn

Over the past 2 years new imaging and therapeutic options using radiolabelled prostate specific membrane antigen have been developed which enable us to see disease which cannot be found by other methods with gallium-68 PSMA PET-CT. Newer work has linked this to targeted radionuclide therapy using beta and alpha emitter labelled PSMA is previously untreatable metastatic prostate cancer which is being actively developed.

EVEN MORE SEMINARS

  • Prof Sam Janes: Speaking at the European Neurological Convention

    Prof Sam Janes
    Delivering CT screening for Lung Cancer in the UK

    Delivering CT screening for Lung Cancer in the UK

  • Estevao Mauricio Bagi: Speaking at the European Neurological Convention

    Estevao Mauricio Bagi
    Royal Brompton & Harefield Hospitals Specialist Care

    Cardiac PET-CT : Rubidium-82 Myocardium Perfusion & 18F-FDG Cardiac Sarcoidosis

  • Dr John Buscombe: Speaking at the European Neurological Convention

    Dr John Buscombe
    British Nuclear Medicine Society

    Theranostics in prostate cancer new or false dawn

  • Sabine Sartoretti: Speaking at the European Neurological Convention

    Sabine Sartoretti
    Institut für Radiologie, Kantonsspital Winterthur, Brauerstrasse 15, 8401 Winterthur

    Compressed Sense Technique in Neuroradiology

  • Sofia Otero: Speaking at the European Neurological Convention

    Sofia Otero
    University College London Hospitals

    Thyroid Radiofrequency Ablation: Our Experience